Matrixx 30% Sales Growth Predicted For 2003 With Zicam Extensions
This article was originally published in The Tan Sheet
Executive Summary
Matrixx Initiatives expects to achieve 30% sales growth in 2003 following a robust revenue gain of almost 50% in 2002, according to President & CEO Carl Johnson